Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-05-06
2010-10-26
Chong, Kimberly (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C536S024310, C536S024100
Reexamination Certificate
active
07820635
ABSTRACT:
RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.
REFERENCES:
patent: 6140126 (2000-10-01), Bennett et al.
patent: 6284741 (2001-09-01), Werther et al.
patent: 6383808 (2002-05-01), Monia et al.
patent: 6436700 (2002-08-01), Roth et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2003/0158130 (2003-08-01), Gleave et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2006/0003322 (2006-01-01), Bentwich
patent: 00/49937 (2000-08-01), None
patent: 00/69454 (2000-11-01), None
patent: 01/05435 (2001-01-01), None
patent: 0136646 (2001-05-01), None
patent: 01/75164 (2001-10-01), None
patent: 02/22635 (2002-03-01), None
patent: 02/22642 (2002-03-01), None
patent: 02/44321 (2002-06-01), None
patent: 02059300 (2002-08-01), None
patent: 03/062421 (2003-07-01), None
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA., Expert Opin. Drug Deliv, 2005, vol. 2(1), pp. 3-28.
Scherer et al., Approaches for the Sequence-specific knockdown of mRNA, Nat. Biotechnol., 2003, 21(12), pp. 1457-1465.
Zangemeister et al., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xI Expression Efficiently Induces Apoptosis in Tumor Cell., Clinical Cancer Research, 2000, vol. 6, pp. 2547-2555.
Zhang et al., Targeted Gene Silencing by Small Interfering RNA based Knock-down Technology, Current Pharmaceutical Biotechnology, 2004, vol. 5, pp. 1-7.
Agami. “RNAi and related mechanisms and their potential use for therapy,” Current Opinion in Chemical Biology , 2002, pp. 829-834, vol. 6, Publisher: Current Biology Ltd, London, GB XP00295888.
Brummelkamp et al. “A system for stable expression of short interfering RNAs in mammalian cells” Science, 2002, pp. 550-553, vol. 296, No. 5567, Publisher: American Association for the Advancement of Science, US, XP002234902.
Calero et al. “Apolipoprotein J (Clusterin) and Alzheimer's Disease” Microscopy Research Technique, 2000, pp. 305-315, vol. 50 No. 4, XP009021345.
Carthew et al. “Gene silencing by double-stranded RNA” Current Opinion in Cell Biology, 2001, pp. 244-248, vol. 13.
Choi-Miura et al. “Relationship between multifunctional protein “Clusterin” and Alzheimer Disease” Neurobiology by Aging, 1996, pp. 717-722, vol. 17, No. 5, XP001146408.
Chacko et al. “Double-Stranded Ribonucleic Acid Decreases C6 Rat Glioma Cell Numbers: Effects on Insulin-Like Growth Factor I Gene Expression and Action”, Endocrinology, Oct. 2000, vol. 141, No. 10 pp. 3546-3555.
Davies et al. Mutations of the BRAF gene in human cancer, Nature, 2002, pp. 949-954, vol. 417.
Demattos et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease, PNAS, 2002, pp. 10843-10848, vol. 99, No. 16.
Demir et al. “Use of RNA Interference (RNAi) to Disrupt C-Kit Gene Expression in Malignant Human Hematopoietic and Neuroepithelial Cells,” Blood, 2000, p. 378B, vol. 96 No. 11, Part 2, Publisher W.B.Sanders Company, Orlando, FL, US, Abstract #5389, XP009004894.
Elbashir et al. “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells” Nature, 2001, pp. 494-498, vol. 411.
Fire et al. “Potent and Specific Genetic Interference by double-stranded RNA in Caenorhabditis elegans” Nature, 1998, pp. 806-811, vol. 391.
Gewirtz “A Critical Evaluation of the Mechanisms of Action Proposed for the Antitumor Effects of the Anthracycline Antibiotics Adriamycin and Daunorubicin,” Biochemical Pharmacology, 1999, pp. 727-741.
Gleave et al. “Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/TestosteroneRepressed Prostate Message 2, to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer” Urology, 2001, pp. 39-49, vol. 58, XP002262320.
Gleave et al. “Targeting anti-apoptotic genes upregulated by androgen withdrawl using antisense oligonucleotides to enhance androgen and chemo-sensitivity in prostate cancer” Investigational New Drugs, 2002, pp. 145-158, vol. 20, No. 2, XP 009021411.
Harborth et al. “Identification of essential genes in cultured mammalian cells using small interfering RNAs” Journal of Cell Science, 2001, pp. 4557-4565, vol. 114.
Hojoh et al. “RNA interference (RNAi) induction with various types of synthetic oligonucleotides duplexes in cultured human cells” FEBS Letters, 2002, pp. 195-199, vol. 521, No. 1-3, Publisher: Elsevier Science Publishers, Amsterdam, NL XP004362164.
Jones et al. “Molecules in focus: Clusterin” The International Journal of Biochemistry & Cell Biology, 2002, pp. 427-431, vol. 34, XP002262319.
Koch-Brand et al. “Clusterin: A Role in Cell Survival in the Face of Apoptosis” Process in Molecular and Subcellar Biology, 1996, pp. 130-149, vol. 16, XP009021385.
Leskov et al. “Synthesis and Functional Analyses of Nuclear Clusterin, a Cell Death Protein” The Journal of Biological Chemistry, 2003, pp. 11590-11600, vol. 278, No. 13.
McGill et al. “Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulated Lineage Survival and Melanoma Cell Viability” Cell, 2002, pp. 707-718, vol. 109.
Miyake et al. “Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo” Clinical Cancer Research, 2000, pp. 1655-1663, vol. 6, No. 5, Publisher: The American Association for Cancer Research, US, XP000960694.
Miyake et al. “Castration-Induced Up-Regulation of Insulin-Like Growth Factor Binding Protein-5 Potentiates Insulin-Like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models” Cancer Research, vol. 60, No. 11, pp. 3058-3064, Jun. 1, 2000.
Miyake et al.“Novel Therapeutic Strategy for Advanced Prostate Cancer using Antisense oligodeoxynucleotides targeting antiapoptotic genes Upregulated after Androgen withdrawl to Delay androgen-independent progression and enhance chemosensitivity” International Journal of Urology, 2001, pp. 337-349, vol. 8, No. 7, XP002262321.
Muller et al. “Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion” Cancer Chemother Pharmacol, 1993, pp. 379-384, vol. 32.
Paddison et al. “Stable suppression of gene expression by RNAi in mammalian cells” Proceedings of the National Academy of Sciences of USA, 2002, pp. 1443-1448, vol. 99, No. 3, Publisher: National Academy of Science, XP002958887.
Pavelic et al. “Insulin-Like Growth Factor Family and Combined Antisense Approach in Therapy of lung Carcinoma” Molecular Medicine, vol. 8, No. 3, pp. 149-157, Mar. 2002.
Rohlff et al. “Prostate Cancer Cell Growth Inhibition by Tamoxifen is Associated With Inhibition of Protein Kinase C and Induction of p21” The Prostate, 1998, pp. 51-59, vol. 37.
Rosenberg et al. “Clusterin: Physiologic and Pathophysiologic Co
Beraldi Eliana
Gleave Martin
Gonos Efstathios
Jansen Burkhard
Signaevsky Maxim
Chong Kimberly
Larson & Anderson LLC
The University of British Columbia
LandOfFree
RNAi probes targeting cancer-related proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi probes targeting cancer-related proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi probes targeting cancer-related proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4164294